Warning: Table './metrobus_MBM/sessions' is marked as crashed and should be repaired query: DELETE FROM sessions WHERE timestamp < 1490425485 in /home/metrobus/public_html/includes/database.mysql.inc on line 136

Warning: Cannot modify header information - headers already sent by (output started at /home/metrobus/public_html/includes/database.mysql.inc:136) in /home/metrobus/public_html/includes/bootstrap.inc on line 726

Warning: Cannot modify header information - headers already sent by (output started at /home/metrobus/public_html/includes/database.mysql.inc:136) in /home/metrobus/public_html/includes/bootstrap.inc on line 727

Warning: Cannot modify header information - headers already sent by (output started at /home/metrobus/public_html/includes/database.mysql.inc:136) in /home/metrobus/public_html/includes/bootstrap.inc on line 728

Warning: Cannot modify header information - headers already sent by (output started at /home/metrobus/public_html/includes/database.mysql.inc:136) in /home/metrobus/public_html/includes/bootstrap.inc on line 729
Content about FDA | Metro Business Media
Share |

Content about FDA

warning: Cannot modify header information - headers already sent by (output started at /home/metrobus/public_html/includes/database.mysql.inc:136) in /home/metrobus/public_html/includes/common.inc on line 148.
August 24, 2011

One of the largest and most profitable biotechnology companies in the Mid-Atlantic is trying to increase its revenue by developing an oral form of treatment for pulmonary arterial hypertension (PAH).

Silver Spring-based United Therapeutics Corporation (NASDAQ: UTHR) released its FREEDOM-C(2) Phase 3 clinical trial results today but the company announced that the study did not meet its primary endpoint.

July 21, 2011

The largest biotech in the Baltimore-Washington area measured by market value said Benlysta is gaining momentum in net sales

After more than a decade of research, development, and waiting more than a year for a delayed FDA approval, Human Genome Sciences, Inc (NASDAQ: HGSI) finally has a drug on the market that it can consistently sell to the healthcare industry.

The Rockville, Md biotechnology company reported Benlysta net sales of $7.8 Million. $1.2 Million in additional sales were excluded due to non-delivery to healthcare providers prior to the release of second quarter financial results.

Increasing Lupus Drug Sales

June 27, 2011

The Chinese Biopharmaceutical Association held its annual event Sunday at the University System of Maryland, Shady Grove Campus in Rockville.

The 16th annual event for the association was represented by a large number of executives from China as well as the United States. The organization's members include scientists, attorneys, entrepreneurs and other professionals. More than four delegations in groups of ten or more attended the event, flying all the way from China.

June 23, 2015

Gaithersburg-based GlycoMimetics (soon to be in North Rockville) received a another large payment from Pfizer.

GlycoMimetics (NASDAQ: GLYC) has entered its Phase 3 clinical trial called RESET (Rivipansel: Evaluating Safety, Efficacy and Time to Discharge) to treat people with sickle cell disease who are six years of age or older.

March 21, 2014

Washington, D.C.-based Vanda Pharmaceuticals Inc (NASDAQ:VNDA), has launched a couple of drugs and even recently put into place a television ad campaign. The company is now in need of extra space and will expand into an additional 8,600 square feet at its D.C. headquarters located at 2200 Pennsylvania Avenue.

Vanda will pay the landlord, Square 54 Office Owner LLC, and additional $381,000 for a 12 year and one month term lease beginning on September 1, 2014, although Vanda will get a nine month grace period.

March 13, 2014

In late 2012 Sucampo Pharmaceuticals (NASDAQ: SCMP) received approval from the Food and Drug Administration (FDA)  to expand upon its gastrointestinal drug -- AMITIZA -- to treat people with opioid-induced constipation (OIC) in the United States.

With increasing competition from other biotechnology companies, that approval is keeping the Bethesda-based drug developer ahead of them and profitable, with a net income posted in 3 out of the last 4 quarters of 2013, including the most recent fourth quarter.

March 13, 2014

Germantown, Maryland-based Intrexon Corporation (NYSE:XON) stock was recently upgraded by EVA Dimensions last week but that doesn’t explain yesterdays price surge of more than 10 percent for the company.

Intrexon was the third most price-trending stock on Google Finance yesterday, the stock price of the company increased more than 11.46 percent (+ $3.14) to close at $30.55 per share.

A few reasons that could have driven Intrexon’s stock price higher,

March 13, 2014

In late 2012 Sucampo Pharmaceuticals (NASDAQ: SCMP) received approval from the Food and Drug Administration (FDA)  to expand upon its gastrointestinal drug -- AMITIZA -- to treat people with opioid-induced constipation (OIC) in the United States.

With increasing competition from other biotechnology companies, that approval is keeping the Bethesda-based drug developer ahead of them and profitable, with a net income posted in 3 out of the last 4 quarters of 2013, including the most recent fourth quarter.

February 28, 2014

Silver Spring, Maryland-based United Therapeutics Corporation (NASDAQ:UTHR) crossed well over $1 billion in revenue for the first time in its corporate history and according to CEO Martine Rothblatt J.D., Ph.D., 2014 will be an even better year.

July 20, 2011

The Rockville based biotechnology company said that  Nicotine Conjugate Immunotherapeutic (NicVAX) did not meet the primary endpoints in the first trial in its Phase III study.

Typically the final stage before a drug is presented for FDA approval and gets the marketing and sales go ahead; the Phase III clinical trials for Nabi Biopharmaceuticals' NicVAX drug may be its' last stop for good.

The Rockville based biotechnology company said that  Nicotine Conjugate Immunotherapeutic (NicVAX) did not meet the primary endpoints in the first trial in its Phase III study.